CVAC News and Press, CureVac N.V. From 12/09/21

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...

CureVac N.V. (CVAC) Q3 2021 Earnings Conference Call November 19, 2021 8:00 AM ET Company Participants Sarah Fakih – Vice President-Corporate Communications and Investor Relations Franz-Werner Haas – Chief Executive Officer Klaus Edvardsen – Chief Development Officer Pier...

Image source: The Motley Fool. CureVac (NASDAQ: CVAC) Q3 2021 Earnings Call Nov 19, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: CureVac (CVAC) Q3 2021 Earnings Call Transcript

Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review Nature publication of promising pre-clinical results for second-generation COVID-19 vaccine candidate, CV2CoV,...

CureVac (NASDAQ:CVAC) announces the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline (NYSE:GSK), in the journal Nature. CVAC shares rise 5.2% premarket at $40.81. The newly published data features a direct comparis...

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the online publication of the extended precli...

- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited; results expected in the second half of 2022 TÜBINGEN, GERMANY and BOSTON, MA / A...

As the FDA moves to approve multiple booster shots for all of the available Covid-19 vaccines available today, concerns are mounting as more studies are suggesting the first wave of vaccinations are waning significantly in efficacy. It’s becoming clearer that the world needs ...

Shares of CureVac (NASDAQ: CVAC) were tumbling 7.4% as of 11 a.m. EDT on Tuesday after falling as much as 13% earlier in the morning. The decline came after the company announced it's withdrawing COVID-19 vaccine candidate CVnCoV from the European Medicines Agency's approval process...

Gainers: Nutriband (NTRBW) +84%, Nutriband (OTCQB:NTRB) +38%, Inhibrx (NASDAQ:INBX) +29%, Titan Pharmaceuticals (NASDAQ:TTNP) +14%, Quanterix (NASDAQ:QTRX) +17%. Losers: Organogenesis (NASDAQ:ORGO) -17%, Trevi Therapeutics (NASDAQ:TRVI) -11%,&...